Articles from Sunflower Therapeutics

Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, today announced that it has completed the sale and installation of several Daisy Petal™ Perfusion Bioreactor Systems at the Serum Institute of India Pvt. Ltd. (SIIPL), part of Cyrus Poonawalla Group, the world’s largest vaccine manufacturer. The installation marks the largest deployment of the Daisy Petal™ to date, highlighting the growing global adoption of perfusion fermentation in commercial vaccine manufacturing.

Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, today announced receipt of the first milestone payment in the ongoing commercialization of a human papillomavirus (HPV) vaccine in collaboration with SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure. This milestone marks the successful completion and demonstration of a tech transfer package for multiple HPV serotypes and is the first in a series tied to commercialization of the 10-valent HPV vaccine candidate.

Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, today announced a Small Business Innovation Research (SBIR) grant of up to $2.36 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). This two-phase grant begins with initial funding of $300,000, with further funds released upon achieving specific milestones. The funding will support Sunflower’s development of an automated, continuous cell disruption platform intended to significantly advance the large-scale production, separation and purification of VLPs for use in cost-effective human vaccines.

Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today that it has engaged Alflow Scandinavia A/S as its exclusive distributor for the Daisy Petal™ Perfusion Bioreactor System in Denmark, Norway, Sweden, and Iceland. This marks Sunflower’s first commercial partnership in Europe, representing a key step in its international growth strategy.

Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today the first system delivery and installation of its Daisy Petal™ Perfusion Bioreactor System to the BioBuilder Education Foundation, a nonprofit offering innovative ways to teach, learn, and explore cutting-edge science and engineering. This marks the first system delivery of the Daisy Petal™ in the United States, a significant step in the company’s ongoing product commercialization.

Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today its exclusive sales representation agreement with Optimal Biotech Group, an authorized manufacturer’s sales representative serving the biotechnology and pharmaceutical market for Northern California and the Pacific Northwest, including British Columbia. Located in one of the largest biotech hubs in the world, Optimal Biotech Group is Sunflower’s first commercial representative established in the United States and Canada, marking a significant step in the company’s ongoing product commercialization.

Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today its first distribution agreement with PharmNXT Biotech, an Indian bioprocessing company. Through this agreement, Sunflower will commercially launch its Daisy Petal™ Perfusion Bioreactor System in Asia, a significant step in the company’s ongoing product commercialization.

Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today the oversubscription of a $3M Simple Agreement for Future Equity (SAFE), which underscores ongoing support for the company’s commercial goals.

Sunflower Therapeutics, a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, today announced that SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, has participated in Sunflower’s simple agreement for future equity (SAFE), a flexible agreement providing future equity rights without immediate valuation, with a $2M subscription to solidify their support for the companies’ ongoing research and development R&D collaborations.